If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

IHH-LITIGATION-DAIICHI-SANKYO:IHH Healthcare’s damages against Daiichi could reach $1.25 billion, expert report says (Feb 6) ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

KUALA LUMPUR, Feb 7 (Bernama) -- IHH Healthcare Bhd’s share price on Bursa Malaysia edged higher in early trading after its unit Northern TK Venture Pte Ltd (NTK) sought compensation from Japan’s ...

IHH Healthcare Bhd’s share price on Bursa Malaysia edged higher in early trading after its unit Northern TK Venture Pte Ltd ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

IHH Healthcare Bhd says its unit is seeking compensation of up to 109.3 billion rupees (RM5.46bil) from Japan’s Daiichi ...

Malaysia’s IHH Healthcare is seeking up to Rs 10,930 crore ($1.25 billion) in damages from Japan’s Daiichi Sankyo for its involvement in Fortis Healt ...

Northern TK Venture raises its damage claim against Daiichi Sankyo to JPY 199.8 billion in ongoing litigation regarding Fortis Healthcares open offer.